Document is current
Any future updates will be listed below
-
Authors
Rattigan, Kevin M.
Brabcova, Zuzana
Sarnello, Daniele
Zarou, Martha M. https://orcid.org/0000-0003-0152-1599
Roy, Kiron
Kwan, Ryan https://orcid.org/0000-0002-6854-3728
de Beauchamp, Lucie
Dawson, Amy
Ianniciello, Angela
Khalaf, Ahmed https://orcid.org/0000-0002-7945-398X
Kalkman, Eric R. https://orcid.org/0000-0002-1108-6589
Scott, Mary T. https://orcid.org/0000-0002-7177-6960
Dunn, Karen https://orcid.org/0000-0002-6532-970X
Sumpton, David https://orcid.org/0000-0002-9004-4079
Michie, Alison M. https://orcid.org/0000-0002-5404-475X
Copland, Mhairi https://orcid.org/0000-0002-7655-016X
Tardito, Saverio https://orcid.org/0000-0002-5294-8683
Gottlieb, Eyal https://orcid.org/0000-0002-9770-0956
Vignir Helgason, G. https://orcid.org/0000-0003-1616-132X
-
Funding
Funding for this research was provided by:
Kay Kendall Leukaemia Fund (KKL1069)
Bloodwise (18006)
Cancer Research UK (C57352/A29754, A25142, A31287, A23982, A31287)
Tenovus
NHS Greater Glasgow and Clyde (GN17ON425, GN17ON425)
- License Information
-
More Information
Article History
Received: 19 October 2022
Accepted: 18 July 2023
First Online: 17 August 2023
Competing interests
: M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals. All other authors declare that they have no competing interests.
